ストックスクリーナーアプリを入手
77.77
0.81%
-0.48
前日終値:
$78.25
開ける：
$78.06
24時間の取引高:
105.13K
Relative Volume:
0.12
時価総額：
$5.33B
収益：
-
当期純損益:
$-146.66M
株価収益率:
-28.24
EPS:
-2.7541
ネットキャッシュフロー:
$-133.21M
1週間 パフォーマンス:
+2.84%
1か月 パフォーマンス:
+1.13%
6か月 パフォーマンス:
+97.81%
1年 パフォーマンス:
+56.59%
1日の値動き範囲:
$76.86
$78.71
1週間の範囲:
$72.56
$80.22
52週間の値動き範囲:
$26.20
$80.99
Apogee Therapeutics Inc Stock (APGE) Company Profile
APGE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
78.00 | 5.35B | 0 | -146.66M | -133.21M | -2.7541 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.99 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
799.17 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
424.91 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
812.47 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.30 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-17 | 開始されました | Stephens | Overweight |
| 2025-12-10 | 開始されました | Deutsche Bank | Buy |
| 2025-11-03 | 開始されました | Craig Hallum | Buy |
| 2025-10-21 | 開始されました | Mizuho | Outperform |
| 2025-09-25 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-07-07 | 繰り返されました | BTIG Research | Buy |
| 2025-03-13 | 開始されました | Citigroup | Buy |
| 2024-11-25 | 開始されました | Canaccord Genuity | Buy |
| 2024-05-10 | 開始されました | BofA Securities | Buy |
| 2023-12-20 | 開始されました | BTIG Research | Buy |
| 2023-08-08 | 開始されました | Guggenheim | Buy |
| 2023-08-08 | 開始されました | Jefferies | Buy |
| 2023-08-08 | 開始されました | Stifel | Buy |
| 2023-08-08 | 開始されました | TD Cowen | Outperform |
| 2023-08-08 | 開始されました | Wedbush | Outperform |
すべてを表示
Apogee Therapeutics Inc (APGE) 最新ニュース
UBS initiates Apogee Therapeutics stock with Buy rating, $100 target By Investing.com - Investing.com Canada
Apogee Therapeutics Inc Stock Analysis and ForecastInstitutional Holding Changes & High Yield Trading Signals - earlytimes.in
UBS initiates Apogee Therapeutics stock with Buy rating, $100 target - Investing.com
Will Apogee Therapeutics Inc. stock benefit from AI adoption2026 world cup usa national team third place match key players pressing system match prediction expert opinion - Улправда
Wolfe Research initiates coverage on Apogee Therapeutics stock with Peerperform rating By Investing.com - Investing.com South Africa
Wolfe Research initiates coverage on Apogee Therapeutics stock with Peerperform rating - Investing.com
One Shot, Six Months of Asthma Relief? Apogee Drug Shows Strong, Long-Lasting Effect In Trial - Benzinga
Apogee Therapeutics (NASDAQ:APGE) Shares Gap DownWhat's Next? - MarketBeat
Apogee Therapeutics Shares Interim Asthma Data Showing Durable FeNO Drop With APG777 Single Dose - MarketBeat
Apogee Therapeutics stock price target raised to $137 by BTIG on asthma data - Investing.com
Apogee Therapeutics stock maintains Outperform rating at RBC on asthma data - Investing.com
Apogee Therapeutics stock falls after asthma trial data By Investing.com - Investing.com India
Apogee Therapeutics Announces Positive Interim Data from Phase 1b Trial of Zumilokibart - TradingView — Track All Markets
Apogee Therapeutics to report interim asthma trial results By Investing.com - Investing.com Nigeria
Apogee Therapeutics Reports Positive Phase 1b Data For Zumilokibart In Mild-to-moderate Asthma - Nasdaq
Apogee Therapeutics rises as asthma drug shows promise in early trial - TradingView — Track All Markets
Apogee Therapeutics Reports Positive Phase 1b Interim Results for Zumilokibart (APG777) in Mild-to-Moderate Asthma and Highlights 2026 Development Milestones - Quiver Quantitative
Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook - GlobeNewswire Inc.
Will Apogee Therapeutics Inc. stock gain from lower inflation2026 world cup usa national team qualification star players possession football match prediction preview - Улправда
Apogee Therapeutics to report interim asthma trial results - Investing.com India
Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026 - The Manila Times
Apogee Therapeutics to Host Conference Call to Report - GlobeNewswire
Apogee Therapeutics (NASDAQ:APGE) Price Target Raised to $128.00 - MarketBeat
(APGE) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Apogee Therapeutics (APGE) Stock Analysis Report | Financials & Insights - Benzinga
Is Apogee Therapeutics Inc a good long term investmentDay Trading Setups & High Return Trading Portfolio - earlytimes.in
Apogee Therapeutics Inc. (NASDAQ:APGE) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Apogee Therapeutics Inc (NASDAQ:APGE) Nasdaq today Early Biotech Stage - Kalkine Media
Apogee Therapeutics Earnings Notes - Trefis
Analysts Are Bullish on These Healthcare Stocks: Apogee Therapeutics (APGE), Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
Apogee Therapeutics stock falls after asthma trial data - Investing.com
BTIG reiterates Buy rating on Apogee Therapeutics stock amid positive outlook By Investing.com - Investing.com South Africa
BTIG reiterates Buy rating on Apogee Therapeutics stock amid positive outlook - Investing.com Australia
Value Recap: What technical signals suggest for Apogee Therapeutics Inc. stockMarket Activity Report & Safe Entry Zone Identification - moha.gov.vn
Henderson, Apogee Therapeutics CFO, sells $120k in stock - Investing.com
Apogee Therapeutics CFO Sells 1,500 Shares - TradingView — Track All Markets
Henderson, Apogee Therapeutics CFO, sells $120k in stock By Investing.com - Investing.com Canada
Apogee Therapeutics (APGE) Gets a Buy from Bank of America Securities - The Globe and Mail
Apogee Therapeutics, Inc. (APGE) Soars on Promising Phase 2 Results for Atopic Dermatitis Drug - MSN
Apogee Therapeutics stock hits all-time high of 78.19 USD - Investing.com
Apogee Therapeutics stock hits all-time high of 78.19 USD By Investing.com - Investing.com Nigeria
Apogee Therapeutics (NASDAQ:APGE) Hits New 12-Month HighWhat's Next? - MarketBeat
Is Apogee Therapeutics Inc. stock a safe investment in uncertain markets2025 Winners & Losers & Safe Capital Growth Tips - DonanımHaber
Apogee Therapeutics (NASDAQ:APGE) Rating Increased to Strong-Buy at Stephens - MarketBeat
Market Outlook: Will Apogee Therapeutics Inc. stock benefit from AI adoptionWeekly Market Summary & Weekly Return Optimization Alerts - ulpravda.ru
Trend Recap: What insider trading reveals about Apogee Therapeutics Inc. stockMarket Movers & Fast Exit and Entry Strategy Plans - Улправда
What insider trading reveals about Apogee Therapeutics Inc. stockQuarterly Trade Summary & Technical Analysis for Trade Confirmation - Улправда
What dividend safety score for Apogee Therapeutics Inc. stockWeekly Trade Report & Risk Managed Investment Entry Signals - ulpravda.ru
How Apogee Therapeutics Inc. stock benefits from global expansionMarket Risk Summary & Daily Stock Trend Reports - Улправда
Stephens Initiates Coverage on Apogee Therapeutics With Overweight Rating, $95 Price Target - marketscreener.com
Stephens & Co. initiates coverage of Apogee Therapeutics (APGE) with overweight recommendation - MSN
Apogee Therapeutics Inc (APGE) 財務データ
収益
当期純利益
現金流量
EPS
0.90%
大文字化:
|
ボリューム (24 時間):